Wir sind mit live! Mehr erfahren

AbCellera Biologics

ABCL

Börsenwert 3,82 Mrd. $

11,80 USD

-0,88

6,94 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

11,80

0,00

0 %

1 Tag

-6,94 %

5 Tage

-7,16 %

1 Monat

1,11 %

3 Monate

91,56 %

6 Monate

208,09 %

Seit Jahresbeginn

244,02 %

1 Jahr

102,05 %

5 Jahre

-22,77 %

10 Jahre

-79,97 %

Profil: AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Mitarbeiter: 562

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 34,8 %

Neutral 60,9 %

Negativ 4,3 %

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

Zacks Investment Research

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.

What'sGoing On With AbCellera Biologics Stock On Tuesday?

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt